

Creating Greater Certainty in the Fight Against Cancer

SynScreen

Large-Scale Syngeneic Screening Opportunity With Reduced Costs

Participate in the Champions Oncology SynScreen for lower cost, large scalesyngeneic studies across 7 lines. Limited Availability.

Enrollment in this study is still possible on a first-come first-served basis.

Take advantage of substantial cost savings now before space runs out. The details on the Champions'

SynScreen are detailed below.

ENROLLMENT ENDING OCTOBER 31ST

The Champions' Synscreen



Baseline Flow Cytometry data is available on all models for response to PD-1, CTLA-4 and OX40

- Only \$375/mouse on study
- Available Models: MC38, CT26, 4T1, LLC, B16/F10, RENCA, and NOW INCLUDING EMT6
- FREE Control group data
- 50% off PD-1, CTLA-4 or OX40 group data
- 20 arms available per model (10 animals/ arm), assigned on a first come first served basis
- Nanostring analysis, flow cytometry and IHC analysis available

Limited Availability

Please contact us today at championsoncology.com/contact-us to learn more about models still available and take advantage of this opportunity before it ends on October 31



Corporate Headquarters One University Plaza, Suite 307 Hackensack, NJ 07601

Phone: 201-808-8400 Toll Free: 866-746-5457 © 2018 Champions Oncology, Inc. All Rights Reserved. Champions TumorGraft is a trademark of Champions Oncology, Inc.